GLG Network Survey: NovoÕs Monlunabant

Please fill out the form to request access to the survey data

SURVEY DETAILS
TARGET POPULATION

For this Network Survey, GLG surveyed 70 endocrinologists/diabetologists, general physicians, and bariatricians across the US and Europe (UK, France, Italy, Spain, and Germany).

What will you learn from this survey?

  • Respondents assessed the safety profile of Monlunabant following its clinical trial, identifying the patient age groups most suitable for the further trials and specifying the subgroups that should be excluded due to potential neuropsychiatric risks.
  • The research explored key factors that could enhance the clinical effectiveness of Monlunabant and its potential role in the future management of obesity.
  • Lastly, experts reviewed the mechanisms underlying weight loss associated with Monlunabant and the expected outcomes in future trials. Respondents also provided insights into their rationale for prescribing, or not prescribing, the drug in the future.

Examples of findings:

  • 65% of respondents stated that possible behavioral disruptions are the main cause of concern for potential neuropsychiatric side effects of Monlunabant drug.
  • 74% of experts stated that doctors/researchers should avoid testing Monlunabant on patients with depression and low mood, while the same percentage expressed concerns about suicidality regarding the drug’s long-term safety and tolerability.
  • 40% of respondents stated that use of CB1 against therapies in pharmacotherapeutic management of adult obesity is considered somewhat important.

Deliverables

The GLG Surveys team drafted the questionnaire with the support of GLG Network Member, Thomas Barber, former Associate Clinical Professor at Warwick Medical School.

  • 1 x Individual responses (“raw data”) in Excel.
  • 1 x PPT report with aggregated data.
  • Executive summary with key takeaways and highlights from the raw data.

Sample Questions

  • By 2030, what proportion of adult patients with obesity would you be able to treat with pharmacotherapies?
  • What are your general perceptions of Monlunabant regarding its overall safety and the ethical concerns surrounding its future prescription?
  • In phase 2a trial, what do you believe contributed to the limited additional weight loss observed with doses above 10 mg per day, specifically at the 20 mg and 50 mg doses?
  • By 2030, what proportion of adult patients with obesity do you expect will be treated with Monlunabant?
  • By 2030, how important will the use of cannabinoid receptor 1 (CB1) inverse agonist therapies be in the pharmacotherapeutic management of adult obesity?
  • Are you aware of the withdrawal of the Rimonabant drug in 2008?
  • What are the reasons for your concerns about the potential neuropsychiatric side effects?

Access

This survey is available to subscribers of the Healthcare (HC) sector (Limited subscriptions and above). This offer includes the raw data file and a high-level presentation through PowerPoint. Please contact your GLG representative for details on your firm’s access.

DISCLAIMER

Please be advised that GLG Network Surveys operate differently than traditional GLG consultations, surveys, teleconferences, etc. and it is advisable that you consult with your firm’s legal and/or compliance department to review your use of the product and the payment for such work under your current subscription. 

By downloading this document and/or participating in the Network Survey, you understand and agree that the information and material provided by GLG, including survey results and survey proposal information, is provided for your own insight and informational purposes only. You further acknowledge and agree that this is a Network Survey for multiple GLG clients, and the results will be provided to all GLG clients that agree to participate in the Network Survey and GLG clients that agree to purchase the Survey results in the future. All survey results do not constitute investment advice or a recommendation. In using this Survey, you agree to hold Gerson Lehrman Group and the Survey respondents harmless and free of all liability as a result of your use of this Network Survey, other than liability resulting from the gross negligence or wilful misconduct of the protected party. You otherwise agree to be bound by Gerson Lehrman Group’s Usage Policies in your interactions with Gerson Lehrman Group and your receipt of services. These Survey results are for are for client’s own use and client shall not redistribute, disseminate, publish, or display the same, in whole or in part, to any third parties or publicly without the prior written permission of Gerson Lehrman Group, except explicitly set forth in your agreement with GLG. This survey will be double-blinded to both client and respondent. GLG reserves the right to restrict the number of clients that can pre-commit access. These Network Surveys are priced outside of standard GLG subscriptions but at a substantially reduced price to commissioning a fully proprietary GLG Network Survey. Upon finding these terms acceptable, please send an affirmative confirmation via email, which GLG will file in its records. Once confirmed, please note that the Client’s agreement to purchase the Network Survey is a legally binding and irrevocable commitment. If the survey is not included within your subscription, GLG will invoice Client for the fees due for the Network Survey. Please note that some respondents may not be Network Members, and the Terms and Conditions of Network Membership would not apply to such respondents and detailed records for them will not be available aside from the information that GLG capture in the Network Survey.